It was reported that soluble AXL could outperform AFP in diagnosing very early hepatocellular carcinoma [45] and correlated with tumor stage as well as patient survival in renal cell carcinoma [46]. This evidence concerns the gene AFP and hereditary clear cell renal cell carcinoma.